8/28/26
Intensity Therapeutics (INTS) Thesis Intensity Therapeutics: the story is balanced — INT230-6 Phase 2 clinical trial data releases (objective response rates, progression-free survival)
★ Analysts see FY2027 revenue reaching $351.0K — -88.3% growth in a single year.
What Moves the Stock 01 INT230-6 Phase 2 clinical trial data releases (objective response rates, progression-free survival) 02 FDA regulatory interactions and trial design agreements (Special Protocol Assessment, breakthrough designation) 03 Partnership or licensing deal announcements with major pharmaceutical companies 04 Equity financing announcements and cash runway updates (dilution concerns) 05 Competitive landscape changes in immuno-oncology and intratumoral therapy space 06 No current revenue - pre-commercial stage 07 Future potential: INT230-6 licensing agreements or partnerships 08 Future potential: Commercial sales post-FDA approval (earliest 2028-2030 estimate) 3.3 4.5 5.8 7.0 8.3 4.45 INTS Daily 4.45 Apr '26 May '26 Jul '26 Aug '26
My Notes growth - Attracts high-risk, high-reward biotech specialists and retail investors seeking asymmetric upside from clinical trial success. Rising rates negatively impact valuation multiples for pre-revenue biotechs as future cash flows are discounted more heavily. Watch on earnings: INT230-6 Phase 2 objective response rate (ORR) and duration of response data, Cash runway and quarterly burn rate trends, NASDAQ Biotechnology Index (NBI) performance as sector sentiment indicator. One Sentence Summary: Intensity Therapeutics: the story is balanced — int230-6 phase 2 clinical trial data releases (objective response rates, progression-free survival).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.